期刊文献+

靶向小分子创新药物 被引量:4

Innovative Medicines of Targeting Small Molecules
原文传递
导出
摘要 寻找药物新靶点是全球创新药物研究激烈竞争的焦点。"组学"、生物信息学、系统生物学、药物筛选现代检测技术等新理论、新技术的发展使新的筛选模型和评价技术不断取得突破。靶向抗肿瘤药物的开发是靶向小分子创新药物的重点任务,多靶点的抗肿瘤药物开发及新靶点的发现是抗肿瘤药物研发的新趋势。 The discovery of new targets is the focus of competition in global new drugs research and development. The sustained breakthrough in screening assays and valuation technology is based on updated theories and technologies of genomics, proteomics, bioin- formatics, system biology, modern detection technology etc. The key task of R&D in targeted small molecular drugs is anti-cancer targeted drugs. The trend of R&D in anti-cancer drugs is design of multi-targets drug and discovery of new targets.
作者 唐军 傅大煦
出处 《现代生物医学进展》 CAS 2010年第20期3997-4000,3972,共5页 Progress in Modern Biomedicine
基金 上海市"科技创新行动计划"重点项目("上海十二五科技发展规划战略研究"软课题)(10692105100)
关键词 新靶标 药物评价 筛选模型 靶向抗肿瘤药物 泛素-蛋白酶体通路(UPS) 极光激酶 RAS蛋白 new targets valuation of drugs model for drug screening anti-cancer targeted-medicines ubiquitin-proteasome system (UPS) Aurora Ras protein
  • 相关文献

参考文献9

二级参考文献152

共引文献44

同被引文献31

  • 1桑国卫.国际医药产业发展特点与我国创新药物研究近况[J].齐鲁药事,2005,24(1):17-22. 被引量:14
  • 2郭映秋.我国生物医药企业竞争情报的需求与获取[J].医学信息学杂志,2007,28(5):435-437. 被引量:3
  • 3Munos B. Lessons from 60 years of phannaceutical innovation[ J].Nat Rev Drug Discov, 2009, 8( 12) :959-68.
  • 4Paul SM, Mytelka DS,Dunwiddie CT, et al . How to improveR&D productivity: the pharmaceutical industry's grand challenge[J]. Nat Rev Drug Discov, 2010, 9(3) :203-14.
  • 5MANNING G, WIAYTE DB, MARTINEZ R, et al. The prolein kinase complement of the human genome[J]. Science, 2002, 298 (5600) : 1912 - 1934.
  • 6SIYUAN L, CHUNYING G, XIANQIANG S, et al. Synthesis and biological evaluation of quinazoline and quinoline bearing 2,2,6, 6-tetramethylpiperidine-N-oxyl as potential epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors and EPR bio-prohe a- gents[J]. Eur JMed Chem, 2012, 49:271 -278.
  • 7FEDERICA V, CATERINA C, ELENA G, et al. Long-lasting in- hibition of EGFR autophosphorylation in A549 tumor cells by in- tracellular accumulation of non-covalent inhibitors [ J ]. Bioorg Med Chem Lett, 2013, 23(19) : 5290 -5294.
  • 8JOHNSTON SR LEARY A. Lapatinib: a novel EGFR/HER2 tyro- sine kinase inhibitor for cancer[ J]. Drugs Today(Barc) , 2006, 42(7) : 441 -453.
  • 9GAURAV G, SUVARNA GK. Synthesis and evaluation of new quinazolone derivatives of nalidixic acid as potential antibacterial and antifungal agents [ J ]. Eur J Med Chem, 2006, 41 (2) : 256 - 262.
  • 10HUDSON ALAN T, LANGLEY C, BECKENHAM K, et al. Sub- stituted heteroaromatic compounds and their use in medicine: WO 96/09294 [ P]. 1996 - 03 - 28.

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部